CTLA4 and hypophysitis: Hypophysitis is an increasingly frequent endocrine toxicity of clinical significance observed in patients on treatment with ICIs, particularly monoclonal antibodies (mAbs) that target cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) [1,2].